Latest News
Ventus Therapeutics Names Three New Members to Board of Directors
7 December 2021 - - Canadian biopharmaceutical company Ventus Therapeutics's Ventus Therapeutics US, Inc business has appointed Jane Henderson, Dolca Thomas, M.D. and Markus Warmuth, M.D. to the company's board of directors, the company sai...
Twist Bioscience Launches Circulating Tumor DNA Reference Controls for Development of Liquid Biopsy Assays
7 December 2021 - - US-based synthetic DNA-based products provider Twist Bioscience Corp. (NASDAQ: TWST) has launched the Twist cfDNA Pan-cancer Reference Standards, a standardized control for use in the development and continuous monitoring of ...
PureTech Advances Wholly-Owned Candidate LYT-300 into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions
7 December 2021 - - US-based biotherapeutics company PureTech Health plc (NASDAQ: PRTC) (LSE: PRTC) has initiated a clinical study of LYT-300 (oral allopregnanolone), PureTech's wholly-owned therapeutic candidate for the potential treatment...
Limbix Raises USD 15m in Series A2 Financing, Bringing Total Funding to USD 31m
7 December 2021 - - US-based prescription digital therapeutic company Limbix has raised USD 15m in series A2 financing from both existing and new investors, bringing total funding to date to USD 31m, the company said.

The round was ...
AstraZeneca and Ionis partner to develop eplontersen for TTR amyloidosis
7 December 2021 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) announced on Tuesday a new global development and commercialisation agreement with US biotechnology company Ionis Pharmaceuticals Inc for eplontersen, former...